MHC class I antigens and tumour-infiltrating leucoites in laryngeal cancer: long-term follow-up

F Esteban¹, M Redondo², M Delgado³, F Garrido⁴ and F Ruiz-Cabello⁴

¹Servicio de Otorrinolaringología, Hospital Universitario 'Virgen de Valme', Seville; ²Servicio de Análisis Clínicos, Hospital Costa del Sol, Marbella, Málaga; ³Cátedra de Medicina Preventiva, Universidad de Cantabria, Santander; ⁴Servicio de Analisis Clínicos e Immunología, Hospital Universitario 'Virgen de las Nieves', Granada, Spain.

Summary Alteration in MHC class I expression may be used by cancer cells to avoid immune destruction. Much experimental evidence supports this idea, although survival studies are very scarce. To investigate whether the presence or absence of HLA-A, -B and -C antigens in laryngeal carcinoma influences survival, a series of 60 primary laryngeal tumours treated surgically and normal tissues were evaluated in frozen sections for the expression of MHC class I antigens and tumour-infiltrating leucocytes (CD3, CD4, CD8, CD11b, CD1, CD20 and CD16), using monoclonal antibodies and the APAAP technique. Long-term follow-up from the patients is available, ranging from 6 to 10 years. Thirteen tumours presented total HLA-ABC loss, five selective losses of HLA-A antigens and one absence of HLA-B antigens. Total losses were statistically associated with several clinical and pathological parameters, but tumour-infiltrating leucocytes. After conducting a prospective study, only T and N staging and scoring according to Glanz's malignancy classification were found to be independently related to patients' outcome. From our data, we conclude that neither complete loss of HLA class I antigens nor tumour-infiltrating leucocytes appear to influence survival in squamous cell carcinoma of the larynx.

Keywords: laryngeal carcinoma; MHC antigens; tumour-infiltrating leucocytes

MHC class I antigens are membrane glycoproteins involved in effective killing by cytotoxic T cells, which require HLA class I compatibility between T cells and target cells (Thorsby, 1982; Festsenstein and Garrido, 1986). Alterations in HLA-ABC expression may be one method used by cancer cells to avoid immune destruction (Garrido, 1987). Decreased HLA expression has been discovered in several human tumours, including breast, lung, skin, colorectal, gastric and laryngeal carcinomas (López-Nevot et al., 1986, 1989; Redondo et al., 1991; Ruiz-Cabello et al., 1989). However, few studies have analysed the mechanisms responsible for such alterations. In previous papers, we investigated changes in the expression of HLA class I antigens during malignant transformation of the laryngeal epithelium and some mechanisms involved (Esteban et al., 1989), and we found several clinical and pathological correlations between HLA-ABC losses and aggressiveness (Esteban et al., 1990a). MHC class II antigens were only found in verrucous cell carcinomas, thus DR expression seems to be associated with tumours with excellent prognosis (Esteban et al., 1990b). On the other hand, laryngeal tumours are often characterised by an inflammatory reaction that follows the growth of neoplastic elements, but its prognostic value and its functional significance remain to be determined. The aim of the present work is to present the long-term results of the series and to evaluate the prognostic significance of MHC class I antigens and tumour-infiltrating leucocytes (TILs) in patients with laryngeal carcinoma after long-term follow-up.

Materials and methods

Patients
Sixty patients with squamous cell carcinoma of the larynx were included in the study. None of them received radiotherapy or chemotherapy before surgery. All were male. Age ranged from 44 to 75 years (average 58.68 years). Tumours were classified as originating from the supraglottic region (33.55%), glottis (18.30%), subglottis (2.33%) and pyriform sinus (3.5%). Four cases were considered transglottic (6.7%). Thus, there were 57 laryngeal and three hypopharyngeal tumours in the study. Surgical techniques consisted of cordectomy (four cases), frontolateral laryngectomy with epiglottoplasty as popularised by Harvey Tucker (two cases), supraglottic horizontal laryngectomy (12 cases) and total laryngectomy (42 cases). Neck dissection was performed at clinical stage IV disease and at stage III as indicated by the presence of or high risk of cervical metastasis and by the specific site of the primary tumour. A total of 22 patients underwent ipsilateral and 18 bilateral functional neck dissections. Radical ipsilateral neck dissection was done in three patients, and a bilateral staged procedure in four. Post-operative radiation therapy was decided on an individual basis by a multispeciality joint tumour board (otolaryngologist, oncologist and pathologist), and radiotherapy was chosen for 29 patients. Basically, radiotherapy was chosen for all T4 and/or node-positive tumours, since functional neck dissection allows pathological staging for the neck. There were four T1, four T2, 37 T3 and 15 T4 carcinomas. Forty-two patients were classified as N0, six N1, eight N2 and four N3. Follow-up ranged from 66 to 112 months, available for all patients. At present, 19 patients have died: 12 patients as a result of the disease (five neck relapses, two pharyngeal recurrences, three cases with pulmonary metastasis, one case with neck relapse and lung metastasis, one stomal recurrence) and there were seven deaths unrelated to the laryngeal disease (one myocardial infarction; 1 car crash; 1 chronic pulmonary obstructive disease; one patient, committed suicide, and three died as a result of other tumours: lung, prostate and oesophagus).

Location and diameter of the primary tumour, T and N pathological staging (according to UICC, 1992 version), number of lymph nodes from the neck dissection and number of lymph node metastases, pathological global staging, blood group and Rh of the patient, patient, committed suicide, and three died as a result of other tumours: lung, prostate and oesophagus).
Pathological analysis

Tumours were classified into three grades by the UICC modified Broders' system (Wahi, 1972), and all were scored according to Glanz's (Glanz, 1984) and Jakobsson's (Jakobsson et al., 1973) grading systems for squamous cancer. In addition, two modifications to the former were included [Crisman et al. (1984) and the authors' modification]. The histological grading of malignancy was based upon the tumour cell population (structure, differentiation, nuclear polymorphism and mitosis) and tumour-host relationship (mode of invasion, stage of invasion, vascular invasion and cellular response). Histological analyses were performed without any knowledge of the clinical stage, treatment or further course of the disease.

Monoclonal antibodies, alkaline immunophosphatase technique

The immunohistochemical technique and monoclonal antibodies against MHC class I antigens were described in previous publications (Esteban et al., 1989, 1990). The following MAbS were included against leucocyte determinants: GRT2, which recognises the common leucocyte antigen CD45 (Huelin et al., 1988); Leu 4, Leu 3a and Leu 2a, against CD3, CD4 and CD8 respectively (Becton Dickinson); Bear-1 against CD11b (Keizer et al., 1985); OKT6 (Ortho) against CD1; GRM1 against CD16 (Ruiz-Cabello et al., 1988); and IOM-1 against CD20 (immunotech).

Interpretation of immunohistological results

A tumour was classified as negative when no staining was detected in any of ten randomly chosen microscopic fields, and as positive when all tumour cells were stained in ten fields. In our series, no specimens showed a heterogeneous pattern of staining for the HLA-ABC antigens (Esteban et al., 1990b). Tumour-infiltrating leucocytes were averaged after counting the number of stained cells in ten microscopic high-power fields.

Statistical analysis

We used the proportional hazards model as specified by Cox (1972). In this model, a positive regression coefficient means an increased risk of death for a given level with respect to the baseline level, whereas a negative coefficient indicates the opposite effect. Selection of the most predictive variables was based on a stepwise algorithm with a nominal significance level of 10%. ANOVA was used to compare groups of tumour-infiltrating leucocytes.

Results

Expression of HLA-A, B, C antigens

Normal laryngeal mucosa was always positive for HLA-ABC antigens. Losses of these antigens were always related to malignancy. We found 13 total losses of HLA-ABC antigens, five selective losses of HLA-A and one of HLA-B antigens.

Study of tumour-infiltrating leucocytes

Analysis of the tumour-infiltrating leucocytes was performed in most cases (50 patients). The infiltrating cells were composed of T cells and some macrophages (Table I). Langerhans cells, natural killer (NK) cells and B cells were sparse. No significant differences were found between MHC class I antigen expression and immunophenotype of TILs.

Survival analysis

The survival analysis calculated from 60 patients showed a high probability of tumour-related death for the T, N and score according to Glanz's classifications (Table II). No discriminating effect on tumour-related death, however, could be detected on the expression status of HLA-A, B or C/βm antigens. In addition, the cell composition in the infiltrates did not affect the frequency of metastasis and the 5 year survival.

Discussion

In addition to genetic alterations, some events are probably needed to acquire the malignant phenotype of a tumour. Thus, cellular malignant transformation is frequently associated with alteration in MHC antigens (Garrido et al., 1993), and these alterations may profoundly affect the way in which the tumour behaves, decreasing or enhancing specific anti-tumour immune mechanisms (Festenstein, 1987). It has been shown in several animal models that the immunogenicity of tumours depends on the expression status of MHC class I antigens of tumour cells (Hämmerling et al., 1987). In a recent study, selective growth arrest and phenotypic reversion of prostate cancer cells by phenylacetate, a non-toxic differentiation inducer, was accompanied by an increased amount of HLA transcripts (Samid et al., 1993). Therefore, regulation of tumour HLA expression might be a strategy for the evasion of immune surveillance by the malignant cells.

Concerning the molecular basis of the defect in HLA class I expression in our tumours, we previously reported (Esteban et al., 1989) by Southern and Northern blot analysis that transcriptional regulation of HLA expression is likely to be involved in this phenomenon. Further evidence supporting this concept includes stimulation studies with γ-interferon (IFN) in tumours with undetectable expression of HLA-A, -B or -C antigens (Ruiz-Cabello et al., 1989), and modulation of MHC class I expression by oncogene activation (Versteeg et al.,

Table II: Coefficients, standard errors and odds ratio for the Cox regression model

| Variable | Coefficient | Standard error | Odds ratio |
|----------|-------------|----------------|------------|
| HLA-ABC  |             |                |            |
| N        | 0.7464      | 0.2881         | 2.1094     |
| T        | 1.0232      | 0.6551         | 3.3307     |
| Glanz's  | 0.7113      | 0.2789         | 2.0366     |

*Means of counting ten microscopic high-power fields.
The prospective study presented here confirms the paramount prognostic implication of T, N and Glanz's score on the relative risk of tumour-related death in our group of patients. It is important to stress these aspects in view of the reliability of our statements on MHC antigen expression and prognosis.

Although our survival results are very conclusive, we are reluctant to accept the idea that there is a null response of immune mechanisms. We cannot rule out different HLA class I expression in residual tumour cells after putatively curative resection, since a small proportion of patients with different expression are frequently present in human tumours (Cordon-Cardo et al., 1991). On the other hand, the increased susceptibility of HLA class I-negative tumours to lysis by NK cells may influence metastatic potential and survival (Kärre et al., 1986), and finally, selective losses of HLA class I allelic products on tumours with positive expression for HLA-A,-B and -C antigens may frequently be present and also influence the metastatic potential (Honma et al., 1994). Our group is currently investigating HLA phenotype in invasive breast carcinomas using anti-HLA polymorphic antibodies, and more than 88.5% of the tumours showed an altered HLA tumour phenotype, when compared with the peripheral blood lymphocytes of each patient (Cabrera et al., 1996). In that paper, HLA-ABC total losses were found in a similar proportion to those in laryngeal carcinomas; however, it seems that those laryngeal tumours presenting 'normal' expression of HLA class I antigens could have allelic losses not shown with the MAbs used in our 1990 study, as demonstrated in breast cancer. Thus, alterations in HLA class I expression could be so common that statistical analysis may not detect the importance of HLA expression in tumour cells.

In conclusion, total loss of HLA-A,-B and -C expression is not a high risk of tumour-related death. Further investigations with HLA allelic typing and other immunological markers are needed to evaluate prognosis in laryngeal carcinomas.
Identification of lymphocyte subsets and natural killer cells in head and neck cancers. Arch. Oto-Rhino-Laryngol., 242, 89–97.

Hiratsuka H, Imamura M, Ishii Y, Kohama G and Kikuchi K. (1984). Immunologic detection of lymphocyte subpopulations infiltrating in human oral cancer with special reference to its clinical significance. Cancer, 53, 2456–2466.

Honma S, Tsukada S, Honda S, Nakamura M, Takakuwa K, Maruhashi T, Kodama S, Kanazawa K, Takahashi T and Tanaka K. (1994). Biological–clinical significance of selective loss of HLA-Class-I allelic product expression in squamous-cell. Int. J. Cancer, 57, 650–655.

Huelin C, Gonzalez M, Pedracini S, de la Higuera B, Piris MA, San Miguel J, Ruiz-Cabello F and Garrido F. (1988). Distribution of the CD45R antigen in the maturation of lymphoid and myeloid series: the CD45R negative phenotype is a constant finding in T CD4 positive lymphoproliferative disorders. Br. J. Haematol., 69, 173–179.

Jakobsen PA, Aenneroth CM, Killander PD, Moberger G and Martensson B. (1973). Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol. Ther. Phys. Biol., 12, 1.

Karre K, Ljunggren HG, Piontek G and Kiessling R. (1986). Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature, 319, 675–678.

Keizer GD, Borst J, Fidger CG, Spits H, Miedema F, Terhorst C and de Vries JE (1985). Biochemical and functional characteristics of the human leukocyte membrane antigen family LFA-1, MO-1 and p150, 95. Eur. J. Immunol., 15, 1142–1155.

Kubota Y, Petras RE, Easley KA, Bauer TW, Tubb BS and Fazio VW. (1992). Ki-67 determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer, 70, 2602–2609.

Lopez-Neto JB, Esteban F, Feron R, Gutierrez J, Oliiva MR, Romero C, Huelin C, Ruiz-Cabello F and Garrido F. (1989). HLA Class I gene expression on human primary tumors and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br. J. Cancer, 59, 221.

Marques LA, Franco EL, Torloni H, Brentani MM, Dasilva-Neto JB and Brentani RR. (1990). Independent prognostic value of laminit receptor expression in breast cancer survival. Cancer Res., 50, 1479–1483.

Moeller P, Momburg F, Koretz K, Moldenhauer G, Herfarth C, Otto HF, Hammerling GJ and Schlag P. (1991). Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res., 51, 729–736.

Passlick B, Izbicki JR, Simmel S, Kubuschok B, Karg O, Habeck M, Theteter O, Schweiberer L and Pantel K. (1994). Expression of major histocompatibility class-I and class-II antigens and intercellular-adhesion molecule-1 on operable nonsmall cell lung cancers: frequency and prognostic significance. Eur. J. Cancer, 30A, 376–381.

Rabin BS, Johnson J and Claassen D. (1984). Identification of subsets of lymphocytes infiltrating head and neck cancer tissue: a preliminary report. Laryngoscope, 94, 688–690.

Redondo M, Concha A, Oldiwa R, Cueto A, Gonzalez A, Garrido F and Ruiz-Cabello F. (1991). Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA-content and clinical-pathological parameters. Cancer Res., 51, 4948–4954.

Ruiz-Cabello F, Lopez-Neto MA and Garrido F. (1988). MHC class I and II gene expression on human tumors. In Cancer Metastasis. Prodi G, Liotta LA, Lollini P-L, Garbisa S, Gorini S and Hellman K (eds) pp. 119–128. Plenum Publishing Corp: New York.

Samid D, Hack S and Myers CE. (1993). Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest., 91, 2288–2295.

Shimokawa I, Imamura M, Yamanaka N, Ishii Y and Kikuchi K. (1982). Identification of lymphocyte subpopulations in human breast cancer tissue and its clinical significance. Cancer, 49, 1456–1464.

Stewart TR and Tsai SC. (1993). The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin. Exp. Metastasis, 11, 295–305.

Thorsby E. (1982). Involvement of HLA Class II membrane molecules in human T cell immune responses: immunological and clinical significance. In HLA Typing: Methodology and Clinical Aspects, vol.2. Ferrone S and Solheim BG (eds) pp. 151–166. CRC Press: Boca Raton, FL, USA.

Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ and Schrijer PI. (1988). C-myc down-regulates class I expression in human melanomas. EMBO J., 7, 1023.

Vose BM and Bonnard GD. (1982). Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells. Nature, 296, 359–361.

WahI PN. (1972). Histological Typing of Oral and Oropharyngeal Tumours. WHO: Geneva.

Wolfgang GT, Hudson JL, Petersen KA, Miller HL and McClatchey KD. (1986). Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck. Correlations with extent of tumour and prognosis. Otolaryngol. Head Neck Surg., 95, 142–152.

Zeromska J, Szyma Z, Revers A and Kruck-Zagajewski A. (1996). Immuno-ﬂuorescent assessment of tumour infiltrating cells in laryngeal carcinoma. Acta Otolaryngol., 102, 325–332.